Tag archive for ‘Glatiramer Acetate’
Niva Goldberg On Thursday, June 18th, 2015

U.S. court invalidates Teva’s Copaxone patent

The U.S. Court of Appeals has again ruled that Teva Pharmaceuticals Industries Ltd.’s patent for its top-selling multiple sclerosis treatment Copaxone is invalid. A Teva spokeswoman said that the company is More...

Jewish Business News On Thursday, May 28th, 2015

Mapi Pharma Closes $10 Million Investment Led by Shavit Capital

– – Israeli biomed firm Mapi Pharma Ltd., which is a development stage pharmaceutical company, received a $10 million investment led by Shavit Capital in a Series A financing round that included More...

Shiri Habib-Valdhorn On Thursday, May 14th, 2015

Three way takeover battle- Teva: We can close Mylan deal in 2015

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) CFO Eyal Desheh remains upbeat about Teva’s attempts to buy Mylan N.V. (Nasdaq: MYL). At the same time, Mylan continues to oppose the takeover More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
Koby Yeshayahou On Tuesday, May 12th, 2015

Three Way Takeover Battle: Mylan mulling improved offer for Perrigo – Bloomberg

Mylan (MYL) is considering an improved offer to shareholders of Perrigo (PRGO) with the aim of acquiring the company and thus heading off the hostile bid for Mylan from Teva Pharmaceutical Industries Ltd. (NYSE: More...

Gil Tanenbaum On Wednesday, December 17th, 2014

Israeli Bio Med Firm Mapi Pharma Makes Headway In MS Medication

Israeli biomed firm Mapi Pharma Ltd., which is a development stage pharmaceutical company, announced that the first patient was treated in the company’s Phase IIa study of a new drug for the treatment More...

Jewish Business News On Thursday, March 27th, 2014

Dutch co reports generic Copaxone study success

– Synthon says its Phase III clinical trial of glatiramer acetate found an equivalent efficacy and safety profile to Copaxone. – – Dutch drug developer Synthon BV today announced success More...

Jewish Business News Service On Wednesday, December 4th, 2013

Teva and Takeda Announce Agreement for Glatiramer Acetate (Copaxone) for Multiple Sclerosis Treatment in Japan

–   Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda Pharmaceutical Company Limited ((TSE: 4502) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda More...

Wordpress site Developed by Fixing WordPress Problems